journal
MENU ▼
Read by QxMD icon Read
search

Current Radiopharmaceuticals

journal
https://www.readbyqxmd.com/read/29766832/northstar-perspectives-for-actinium-225-production-at-commercial-scale
#1
James T Harvey
Actinium-225, and its daughter bismuth-213, have great promise in alpha immuno therapy (AIT) for treatment of various disease modalities. Unfortunately, current production levels of actinium-225 that are commercially available do not support broad use of either actinium-225 or bismuth-213 in development or use for disease treatment. Further, the current cost per millicurie is much too high to be sustainable long term in the market. Resolution of both supply and cost issues allows clinical research to proceed through clinical trials and potentially produce one or more effective therapies for cancer or infectious diseases that could benefit the public...
May 15, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29745348/automated-synthesis-of-68ga-dota-toc-methodological-aspects-and-suitable-technical-solutions-for-a-cationic-purification-system
#2
Licia Uccelli, Alessandra Boschi, Corrado Cittanti, Petra Martini, Luca Lodi, Elisa Zappaterra, Simona Romani, Samanta Zaccaria, Davide Cecconi, Ilaria Rambaldi, Ivan Santi, Stefano Panareo, Melchiore Giganti, Mirco Bartolomei
The PET Gallium-68 isotope has the advantage of being produced from a generator, so it is also available in nuclear medicine departments without a cyclotron. The preparation of Ga-68 DOTA-labelled compounds is actually performed by remotely controlled automated systems developed in order to assure production efficiency, reproducibility of the results, guarantee fast reaction time, to facilitate the synthesis and minimize the radiation exposure. Many automatic synthesis systems are available on the radiopharmaceutical market, and each of these requires the realization of some technical adaptations for routine use...
May 8, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29732998/an-overview-of-targeted-alpha-therapy-with-225actinium-and-213bismuth
#3
Alfred Morgenstern, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki, Frank Bruchertseifer
Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy. This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
May 1, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29697036/dosimetry-and-radiobiology-of-alpha-particle-emitting-radionuclides
#4
George Sgouros, Robert Hobbs, Anders Josefsson
Radiopharmaceutical therapy is a cancer treatment modality by which radiation is delivered directly to targeted tumor cells or to their microenvironment. This makes it possible to deliver highly potent alpha-particle radiation. The short-range and highly potent nature of alpha-particles requires a dosimetry methodology that considers microscale distributions of the alpha-emitting agent. The high energy deposition density along an alpha-particle track causes a spectrum of DNA lesions. The majority of these are irreparable DNA double-stranded breaks...
April 26, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29683101/in-vivo-evaluation-of-free-and-chelated-accelerator-produced-actinium-225-radiation-dosimetry-and-toxicity-results
#5
Zewei Jiang, Ekaterina Revskaya, Darrell R Fisher, Ekaterina Dadachova
OBJECTIVE: The demand for the alpha-emitting radionuclide Actinium-225 (225Ac) for use in radionuclide therapy is growing. Producing 225Ac using high energy linear accelerators, cyclotrons or photoinduction could increase its supply. One potential problem with accelerator produced 225Ac using Thorium-232 targets is the presence in final product of 0.1-0.3% by activity of the long-lived 227Ac impurity at the end of irradiation. It is important to comprehensively evaluate the behavior of accelerator-produced 225Ac in vivo before using it in pre-clinical and clinical applications...
April 23, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29676240/motion-management-in-pet-ct-technological-solutions
#6
Elena De Ponti, Sabrina Morzenti, Cinzia Crivellaro, Federica Elisei, Andrea Crespi, Luca Guerra
BACKGROUND: Motion due to patient's breathing can introduce heavy bias in PET/CT, both in image quality and quantification. AIM: To review technical aspects of the main solutions available to manage movement in PET/CT studies. METHODS: The following tools were described: Respiratory Gated (RG), Motion Free (MF), End Expiration (EE), Banana Artefact Management (BAM) and Data Driven Gating (DDG). RESULTS: The most diffused solutions (RG, MF, EE) are based on LIST mode acquisition of a PET Field of View (4D FOV), centered on the anatomical region of interest; to link PET data not only to time and to spatial position but also to the corresponding breathing phase, the synchronized acquisition of the patient's breathing curve is performed by an external tracking device...
April 19, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29669509/the-production-of-ac-225
#7
Jonathan W Engle
The radionuclide 225Ac and its daughter 213Bi are among the most interesting alpha emitters being evaluated for incorporation into targeted therapeutic vectors. Global supply of 225Ac is presently insufficient to meet anticipated clinical demand, but the deficiency has been targeted by many research and development efforts, privately and publicly funded. From more than a decade of these endeavors, no single production technology has emerged as a complete solution. In the foreseeable future, global supply of 225Ac will continue to be sourced from a patchwork of production methods and laboratories with a range of radioisotopic purities and achievable yields...
April 18, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29667558/ga-68-nanoparticles-and-ultra-small-nanoparticle-next-generation-of-pet-radiopharmaceuticals
#8
Mohammed Al-Qahtani, Yousif Al Malki, Hadeel Mutwali, Edward Helal-Neto, Ralph Santos-Oliveira
BACKGROUND AND OBJECTIVE: The future of medicine relies on the capability to forecast the future and in the development of new drugs. The same rationale is applied to radiopharmacy. In this direction the development of nano-radiopharmaceuticals represents the most effective glance of the future. METHODS: In this manuscript we developed an efficient, rapid and direct methodology to label ultra-small polymeric nanoparticle (10 to 12 nm) and regular polymeric nanoparticles (200 to 210 nm), both obtained by double emulsion technique, with Ga-68 in order to promote the development of PET-nanoradiopharmaceuticals...
April 17, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29658444/development-of-225ac-radiopharmaceuticals-triumf-perspectives-and-experiences
#9
A Kh Robertson, C F Ramogida, P Schaffer, V Radchenko
The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide. Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of 225Ac. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate 225Ac from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields...
April 16, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29651974/preparation-and-dosimetry-evaluation-of-a-carrier-free-90y-labeled-dotmp-as-a-promising-agent-for-bone-marrow-ablation
#10
Nafise Salek, Sara Vosoghi, Simindokht Shirvani Arani, Ali Bahrami Samani, Mohsen Mehrabi, Mohammad Ghannadi Maraghe
BACKGROUND AND OBJECTIVE: Skeletal uptake of 90Y-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) is used to deliver high doses of this radiopharmaceutical to the bone marrow. METHODS: In this research, carrier-free (c.f.) 90Y was obtained from an electrochemical 90Sr/90Y generator. The c.f. 90Y was mixed with 300 µL of DOTMP (20 mg/mL) and incubated under stirring conditions at room temperature for 45 min. RESULTS: The [90Y]Y-DOTMP that was obtained under optimized reaction conditions had the high radiochemical purities (>98%)...
April 12, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29651945/modeling-of-a-cyclotron-target-for-the-production-of-11c-with-geant4
#11
Andrea Chiappiniello, Federico Zagni, Angelo Infantino, Sara Vichi, Gianfranco Cicoria, Maria Pia Morigi, Mario Marengo
BACKGROUND: In medical cyclotron facilities, 11C is produced according to the 14N(p,α)11C reaction and widely employed in studies of prostate and brain cancers by Positron Emission Tomography. It is known from literature [1] that the 11C-target assembly shows a reduction in efficiency during time, meaning a decrease of activity produced at the end of bombardment. This effect might depend on aspects still not completely known. OBJECTIVE: Possible causes of the loss of performance of the 11C-target assembly were addressed by Monte Carlo simulations...
April 12, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29624156/letter-to-the-editor-international-consensus-radiochemistry-nomenclature-guidelines
#12
Heinz H Coenen, Antony D Gee, Michael Adam, Gunnar Antoni, Cathy S Cutler, Yasuhisa Fujibayashi, Jae Min Jeong, Robert H Mach, Thomas L Mindt, Victor W Pike, Albert D Windhorst
No abstract text is available yet for this article.
2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29624155/preface
#13
Luigi Mansi, Sean L Kitson
No abstract text is available yet for this article.
2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29437030/preliminary-human-radiation-dose-estimates-of-pet-renal-agents-para-18-f-fluorohippuric-acid-and-ortho-124-i-iodohippuric-acid-from-rat-biodistribution-data
#14
Mohsen Cheki, Maryam Papie, Luigi Mansi, Sean Kitson, Hariprasad Gali
BACKGROUND: Para-18F-fluorohippuric acid (18F-PFH) and ortho-124I-iodohippuric acid (124IOIH) were recently identified as potential radiotracers suitable for conducting renography using positron emission tomography (PET). The aim of this work was to estimate preliminary human-equivalent internal radiation dose of 18F-PFH and 124I-OIH using the biodistribution data reported in healthy rats. The results were compared with the absorbed dose data of technetium-99m-mercaptoacetyltriglycine (99mTc- MAG3) as documented in the International Commission on Radiological Protection (ICRP) publication 80...
2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29412126/quantification-of-radiation-exposure-of-non-dominant-index-for-the-surgeon-performing-sentinel-lymph-node-removal-procedure
#15
Claudiu Peştean, Maria Iulia Larg, Elena Bărbuş, Claudiu Bădulescu, Doina Piciu
BACKGROUND: Sentinel lymph-node scintigraphy is a useful method for accurate staging of different tumors and a helpful tool in personalized therapy for oncological patients. The radiation exposure for surgical staff has been a concern since the sentinel lymph-node detection method was developed. OBJECTIVE: The objective of the study was to determine and quantify the exposure to radiation of the non-dominant index for the surgeon performing sentinel lymph-node removal and to determine, if there is an irradiation risk imposed during the surgical procedure...
2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29284398/mechanisms-of-radiation-bystander-and-non-targeted-effects-implications-to-radiation-carcinogenesis-and-radiotherapy
#16
Rasoul Yahyapour, Elahe Motevaseli, Abolhasan Rezaeyan, Hamid Abdollahi, Bagher Farhood, Mohsen Cheki, Masoud Najafi, Vilmar Villa
Knowledge of radiobiology is of paramount importance to be able to grasp and have an in-depth understanding of the consequences of ionizing radiation. One of the most important effects of this physical stressor's interaction to targeted and non-targeted cells, tissues and organs is on the late effects on the development of primary and secondary cancers. Thus, an in-depth understanding of the mechanisms of radiation carcinogenesis remain to be elucidated, and some studies have demonstrated or proposed a role of non-targeted effect in excess risk of cancer incidence...
December 29, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29243585/review-the-role-of-radiolabeled-dota-conjugated-peptides-for-imaging-and-treatment-of-childhood-neuroblastoma
#17
Natasha Alexander, Reza Vali, Hojjat Ahmadzadehfar, Amer Shammas, Sylvain Baruchel
Childhood neuroblastoma is a heterogenous disease with varied clinical presentation and biology requiring different approaches to investigation and management. Meta-iodobenzylguanidine (MIBG) is an essential component of metastatic staging for neuroblastoma and has been used as a treatment strategy for relapsed and refractory neuroblastoma. However,10% of children with neuroblastoma will have 123I-MIBG non-avid imaging and up to 60% with relapsed and refractory neuroblastoma will require further treatment with 131I-MIBG, alternative radioisotopes have been investigated for imaging and treatment...
December 14, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29231149/radiopharmaceuticals-labelled-with-copper-radionuclides-clinical-results-in-human-beings
#18
Giulia Anna Follacchio, Maria Silvia De Feo, Francesco Monteleone, Giuseppe De Vincentis, Mauro Liberatore
Positron emission tomography (PET) is an instrumental diagnostic modality based on the representation (by images or numeric parameters) of the spatial and temporal distribution of molecules labelled with positron-emitting radionuclides. PET makes it possible to study biochemical processes underlying the function of several organs, providing information otherwise achievable only with bioptic assessment. PET has been developed around the positron-emitting radioisotopes of biologically important elements such as carbon, oxygen and nitrogen (11C, 15O, 13N), which enable PET imaging to identify the biodistribution of a wide range of small molecules...
December 11, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29231148/pet-radiopharmaceuticals-in-brazil-and-belarus-economic-comparison-using-the-case-of-18fdg
#19
Sviatoslav Brinkevich, Leonardo Paredes Pires, Filipe Leal Portilho, Ralph Santos-Oliveira
The production of radiopharmaceuticals, especially the PET ones, is a complex combination of economic and social factors. Despite the social aspects, that are essential, the economic issue must be considered and play an important parameter for the implementation and maintenance of producer centers around the world, with especial regards for countries which face economic crisis and/or belongs to aegis of under development countries. In order to evaluate this scenario with carried out this study, comparing a well-established producer center in Brazil and a new on in Belarus...
December 11, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/28956517/synthesis-of-18f-2b-srf101-a-sulfonamide-derivative-of-the-fluorescent-dye-sulforhodamine-101
#20
Ingrid Kreimerman, Williams Porcal, Silvia Olivera, Patricia Oliver, Eduardo Savio, Henry Engler
BACKGROUND: The red fluorescent dye Sulforhodamine 101 (SR101) has been used in neuroscience research as a useful tool for staining of astrocytes, since it has been reported as a marker of astroglia in the neocortex of rodents in vivo. The aim of this work is to label SR101 with positron emission radionuclides, in order to provide a radiotracer to study its biological behavior. This is the first attempt to label SR101 by [18F], using a chemical derivatization via a sulfonamidelinker and a commercially available platform...
November 10, 2017: Current Radiopharmaceuticals
journal
journal
41909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"